DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for Charcot-Marie-Tooth disease type 2J — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCharcot-Marie-Tooth disease type 2J maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for charcot-marie-tooth disease type 2j is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
myelin protein zero (MPZ) — MPZ is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8IIA · 2.09 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Charcot-Marie-Tooth disease type 2J is not mentioned in any of the provided abstracts. The abstracts cover other forms of CMT and related conditions. One abstract describes three cases of mitochondrial myopathy, neuropathy and gastrointestinal encephalopathy (MNGIE) that initially presented with a peripheral neuropathy resembling CMT. The diagnosis in all three cases was made only after the patients developed eye signs and abdominal complaints. The authors recommend that young patients with mutation-negative CMT should be followed up to monitor for signs of MNGIE.
A 2023 case report describes a 76-year-old woman with CMT1A, the most common form of CMT, who had a history of pain attacks and hearing loss from a young age, with motor symptoms manifesting late in life. The authors raise the possibility that neuropathic pain and hearing loss may precede the classic motor symptoms of CMT1A. A 2022 case report describes a novel mutation in the MPZ gene causing early-onset but slow-progressive CMT in a Russian family. A 1994 article discusses orthotic management of CMT, presenting four case studies with different clinical pictures and emphasising that muscle grades, gait patterns, and knowledge of the disease's natural history help practitioners provide successful orthotic management.
No drug, treatment, or clinical trial for any form of CMT is mentioned in any of these abstracts. There are no data on survival, response rates, or sample sizes for any therapeutic intervention. What is missing for CMT type 2J specifically is any genetic or clinical data from these abstracts, as well as any funded trials, validated biomarkers for patient stratification, or animal models that could support a repurposing hypothesis.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
BMJ Case Reports · 2009 · 7 citations · open access
AbstractCharcot-Marie tooth disease (CMT) is a heterogenous group of peripheral neuropathies caused by various genetic defects. Three cases of mitochondrial myopathy, neuropathy and gastrointestinal encephalopathy (MNGIE) which initially presented with a peripheral neuropathy resembling CMT are described here. The diagnosis in all three cases was made after they developed eye signs and abdominal complaints. Young patients with mutation negative CMT should be followed up to monitor for signs of MNGIE.
JPO Journal of Prosthetics and Orthotics · 1994 · 1 citations
Orthotic Management of Charcot-Marie-Tooth
AbstractCharcot-Marie-Tooth Disease (CMT) is a neurological condition not commonly seen by orthotists. This article will review recent literature on histology, physical symptoms and classifications. Specific physical manifestations are discussed and illustrated. Four case studies are presented with each having a different clinical picture. Muscle grades and gait patterns as well as a knowledge of this disease's natural history will help practitioners to better provide successful orthotic management.
Internal Medicine · 2023 · 1 citations · open access
An Elderly Woman with Complaints of Pain and Hearing Loss, Diagnosed with CMT1A with <i>PMP22</i> Duplication
AbstractCharcot-Marie-Tooth (CMT) disease is a heterogeneous hereditary motor and sensory neuropathy of the peripheral nervous system, with CMT1A in particular being the most common form. We encountered a 76-year-old woman with CMT1A who had a history of pain attacks and hearing loss from a young age, with motor symptoms manifesting late in life. Her pain and hearing loss may have been related to CMT. Our case also raises the possibility that neuropathic pain and hearing loss may precede the classic motor symptoms of CMT1A.
INDIGO (University of Illinois at Chicago) · 2022 · 0 citations · open access
sj-pdf-2-imr-10.1177_03000605221139718 - Supplemental material for Novel mutation in the <i>MPZ</i> gene causes early-onset but slow-progressive Charcot–Marie–Tooth disease in a Russian family: a case report
AbstractSupplemental material, sj-pdf-2-imr-10.1177_03000605221139718 for Novel mutation in the <i>MPZ</i> gene causes early-onset but slow-progressive Charcot–Marie–Tooth disease in a Russian family: a case report by Anastasiya Aleksandrovna Kozina, Natalia Vladimirovna Baryshnikova, Anna Yurievna Ilinskaya, Anna Alexandrovna Kim, Nikolay Alekseevich Plotnikov, Nadezhda Andreevna Pogodina, Ekaterina Ivanovna Surkova, Peter Alekseevich Shatalov and Valery Vladimirovich Ilinsky in Journal of International Medical Research
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
